One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2020-134398
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 13 |
Affiliation: Memorial Sloan Kettering Cancer Center, Freeman Hospital, Spedali Civili di Brescia, Northwestern University, Takeda (United States), Millennium Engineering and Integration (United States), Seagen (United States), University of British Columbia, Spinal Cord Injury BC, Health Sciences Centre, The Christie NHS Foundation Trust, Universitätsmedizin Göttingen, University of Bologna, University of Debrecen, Saitama Medical University, Odense University Hospital, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Tokyo National Hospital, Calvary Mater Newcastle Hospital, Essen University Hospital, University Hospital Hradec Králové, Centre Hospitalier Universitaire de Lille, Samsung Medical Center, China Medical University Hospital, China Medical University, CDG Therapeutics (United States), University of Virginia, Stanford Blood Center, Institut Català d'Oncologia, University of Washington Medical Center, Hackensack University Medical Center
The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
